Measuring and Valuing Outcomes
We have established an excellent reputation for leading innovative, ideas-driven, and theoretically sound research on the measurement and valuation of outcomes. Health care systems should put patient-relevant outcomes at the heart of decisions about funding and providing health and social care.
To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement
2 March 2022
This blog post is the second in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post…
When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies
1 March 2022
Generic preference-based measures are often used for capturing patients’ health-related quality of life (QOL) to assess quality-adjusted life years (QALYs) in health technology assessment (HTA). Whilst…
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
1 January 2022
A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the…
Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
16 June 2021
Our new paper explores the evidence currently being used to allocate budgets between public sector activities in the UK and its limitations. We argue that there…
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
1 December 2021
Outcome-based payment (OBP) is a flexible payment mechanism linking the price the NHS pays for a medicine to the outcomes it achieves in practice for NHS…
OHE at HESG Winter 2021
11 January 2021
Members from the team at OHE attended the Health Economists’ Study Group (HESG) Winter 2021 Meeting, hosted online by the Centre for Health Economics in London,…
How is Quality of Life Measured for Health Technology Assessments?
1 July 2021
Cost-effectiveness analysis (CEA) is the economic evaluation method that is typically preferred by health technology assessment agencies. Quality-adjusted life years (QALYs) – a composite measure of quality and…
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
Using medicines in combination can deliver better outcomes for patients across different tumour types and disease stages. Yet many HTA agencies do not find that the…
Should We ‘Drop Dead’ from Health State Valuation?
10 December 2020
In a new OHE Research Paper, Chris Sampson, David Parkin, and Nancy Devlin consider whether ‘dead’ must be used as an anchor in health state valuation.…